Novo Nordisk AS (MEX:NOVOBN) ROCE %: 78.97% (As of Mar. 2026)


MEX:NOVOBN Novo Nordisk AS MEX:NOVOBN
79 GF Score
Price MXN810.00
GF Value MXN2,387.36
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS ROCE %?

Novo Nordisk AS MEX:NOVOBN +3.85% 79 ROCE % is 78.97% as of Mar. 2026. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novo Nordisk AS's annualized ROCE % for the quarter that ended in Mar. 2026 was 78.97%.

Novo Nordisk AS  (MEX:NOVOBN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novo Nordisk AS ROCE % Related Terms

Novo Nordisk AS ROCE % Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS ROCE % Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.68 61.19 75.34 69.48 46.11

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.82 58.25 34.13 41.54 78.97
MEX:NOVOBN
79GF Score
Novo Nordisk AS MEX:NOVOBN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS ROCE % Calculation

Novo Nordisk AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=380379.728/( ( (1363507.897 - 637240.744) + (1532567.813 - 608793.313) )/ 2 )
=380379.728/( (726267.153+923774.5)/ 2 )
=380379.728/825020.8265
=46.11 %

Novo Nordisk AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=732665.424/( ( (1532567.813 - 608793.313) + (1559751.988 - 627999.732) )/ 2 )
=732665.424/( ( 923774.5 + 931752.256 )/ 2 )
=732665.424/927763.378
=78.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 78.97% mean?
Novo Nordisk AS (MEX:NOVOBN) has a ROCE % of 78.97% as of Mar. 2026.
Is Novo Nordisk AS's ROCE % too high?
Novo Nordisk AS's current ROCE % is 78.97%. The Drug Manufacturers industry median ROCE % is 7.00. Novo Nordisk AS's value of 78.97% is 1028.9% above this industry median. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's ROCE % compare to LLY and JNJ?
Novo Nordisk AS's ROCE % of 78.97% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Novo Nordisk AS's value of 78.97% is 1028.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current ROCE % of 78.97% is 1028.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current ROCE % is 78.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current ROCE % is 78.97% and 1028.9% above the Drug Manufacturers industry median of 7.00. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current ROCE % is 78.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NOVOBN:

  • ROCE %: 78.97%
  • GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs
  • Industry Position: 1028.9% above the Drug Manufacturers median

No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score

Get the complete analysis for MEX:NOVOBN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN2,387.36
GF Value